Artivion (NYSE:AORT) Upgraded to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Artivion (NYSE:AORT) from a buy rating to a strong-buy rating in a report released on Saturday.

A number of other equities analysts have also recently commented on AORT. Needham & Company LLC boosted their price target on shares of Artivion from $50.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. JMP Securities boosted their price target on Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a research note on Friday, October 10th. Citigroup reiterated an “outperform” rating on shares of Artivion in a research note on Friday, October 10th. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Finally, Stifel Nicolaus boosted their price objective on shares of Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, September 29th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.11.

Artivion Trading Up 0.3%

Shares of AORT opened at $45.71 on Friday. Artivion has a 12-month low of $21.97 and a 12-month high of $48.04. The firm has a market capitalization of $2.17 billion, a P/E ratio of -108.84 and a beta of 1.65. The firm has a 50-day moving average price of $42.69 and a 200 day moving average price of $36.27. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. The company had revenue of $113.39 million for the quarter, compared to the consensus estimate of $110.71 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company’s quarterly revenue was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Artivion will post 0.37 EPS for the current year.

Insider Transactions at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 4,993 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $45.86, for a total value of $228,978.98. Following the transaction, the senior vice president directly owned 56,641 shares of the company’s stock, valued at $2,597,556.26. This represents a 8.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Amy Horton sold 3,482 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $45.86, for a total value of $159,684.52. Following the completion of the transaction, the chief accounting officer owned 141,380 shares in the company, valued at $6,483,686.80. This represents a 2.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 121,477 shares of company stock worth $5,490,695 in the last three months. 7.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Schonfeld Strategic Advisors LLC raised its stake in shares of Artivion by 50.1% during the third quarter. Schonfeld Strategic Advisors LLC now owns 22,141 shares of the company’s stock worth $937,000 after buying an additional 7,392 shares during the last quarter. Amundi acquired a new stake in Artivion during the 3rd quarter worth $297,000. Osterweis Capital Management Inc. raised its position in shares of Artivion by 99.7% during the 3rd quarter. Osterweis Capital Management Inc. now owns 240,772 shares of the company’s stock valued at $10,194,000 after acquiring an additional 120,192 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of Artivion by 235.5% in the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after purchasing an additional 313,446 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Artivion during the third quarter worth $131,000. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.